Phio Pharmaceuticals Corp. - Common Stock (NQ:PHIO)

0.8132 -0.0006 (-0.07%)

Delayed Quote Updated: 4:00 PM EST, Nov 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Phio Pharmaceuticals Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting

November 09, 2026

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced today that clinical data from its Phase 1b trial were presented at the 2026 Annual Meeting of the American Society for Dermatologic Surgery (ASDS),...

Via B2i Digital

Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting

November 09, 2026

INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma; Potential to Decrease Morbidities and Surgical Fatigue

Via Newsfile

Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)

November 06, 2026

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced today that it will present clinical data from its Phase 1b clinical trial at the 41st Annual Meeting of the Society for Immunotherapy of Cancer...

Via B2i Digital

Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation

November 06, 2026

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) today reported financial results for the quarter ended September 30, 2026, and provided a business update.

Via B2i Digital

Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)

November 06, 2026

INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma

Via Newsfile

Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation

November 05, 2026

PH-762 Program Accomplishes Major Development Milestones Including Completion of Commercial-Scale cGMP Manufacturing, Treatment in Long-Term Toxicology Study, and Submission of Key Regulatory Documents...

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

October 19, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance

October 13, 2026

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) today announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), representing a...

Via B2i Digital

Topics Economy

Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance

October 13, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing...

Via Newsfile

Topics Economy

OTC Markets Group Announces Third Annual Global Markets Forum Presentations Now Available On Demand

October 12, 2026

View presentations from European and Canadian public growth companies following the October 7–8 event

From Virtual Investor Conferences

Via GlobeNewswire

Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026

October 06, 2026

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) today announced that Robert Bitterman, President and Chief Executive Officer, will present Phio’s INTASYL® siRNA therapeutic platform at The Global Markets...

Via B2i Digital

Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026

October 06, 2026

Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.com

Via Newsfile

Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference

October 05, 2026

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) today announced that it has accepted the invitation to present at the National Investment Banking Association’s (NIBA) 153rd Conference on October 6-7, 2026,...

Via B2i Digital

Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference

October 05, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - October 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing...

Via Newsfile

Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference

September 23, 2026

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) today announced that it will present at the Life Sciences Future 2026 Conference, taking place September 30 to October 1, 2026, at the Sheraton Valley Forge...

Via B2i Digital

Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference

September 23, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing...

Via Newsfile

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

September 14, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 11, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing...

Via Newsfile

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894

August 11, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing...

Via Newsfile

Topics Intellectual Property

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

August 06, 2026

Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase...

Via Newsfile

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

July 22, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

July 22, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

July 21, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision

July 15, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Topics Intellectual Property

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

June 26, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

June 26, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026

June 25, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762

June 24, 2026

Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substanceNewly manufactured supply will support upcoming clinical trial in...

Via Newsfile

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

June 23, 2026

Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026

June 18, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.